dm+d

Unassigned

New Medicines

Coeliac disease

Information

New molecular entity
9 Meters Biopharma
9 Meters Biopharma

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Jun 22PIII CedLara trial discontinued due to disappointing interim results. [13]

Category

Cell membrane permeability inhibitor (oligopeptide)
Coeliac disease affects about 1% of people in the US and EU [2].
Coeliac disease
Oral